C
Centenara Labs
Creating therapies to improve healthy aging, based on experienced drug discovery
About Centenara Labs
Rejuveron is a biotech startup that focuses on developing therapies to combat the effects of aging. The company operates in the healthcare market, specifically in the field of drug discovery and development. Its primary clients are individuals seeking to age better and live longer.
Read full description
Rejuveron's business model revolves around creating a pipeline of breakthrough therapeutics that address the hallmarks of aging. These include DNA damage and mutation, senescent cells, telomere shortening, deregulated nutrient sensing, mitochondrial dysfunction, and stem cell exhaustion.
As cells age, their DNA accumulates damage and mutations, and their repair mechanisms start to fail. This promotes aging and disease. Senescent cells, or "zombie cells," are cells that should have died but instead stay alive and negatively affect other cells, causing associated diseases. Rejuveron aims to prevent the accumulation of these cells.
Telomeres, the ends of our chromosomes, get shorter as cells divide, causing cells to age and stop functioning properly. High metabolic activity can stress cells and cause them to age, but when nutrients are limited, cells enter a regenerative mode, which can increase lifespan. Rejuveron is working on mimicking this process to increase health and lifespan in humans.
Mitochondria, the powerhouse of cells, build up oxidative stress and mutations with age, leading to cellular dysfunction and aging. Additionally, stem cells lose their ability to differentiate and replace cells throughout the body as we age, leading to a weak immune system. Rejuveron is developing therapies to address these issues.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Schlieren, Switzerland
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 63.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, EIT Health, Hard Tech, Longevity, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 3 companies, latest Dec 2021
- Capital deployed
- $45M
- Preferred round
- SERIES A
Latest news
Press, funding announcements and product moves mentioning Centenara Labs.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SUPPORT PROGRAMOther financing | Jan 2024 | $1K | — | EIT Health | — |
| SERIES BOther financing | Sep 2023 | $75M | $300M | Mubadala Capital · Apeiron Investment Group · Catalio Capital Management | ↗ |
Growth signals
Latest recorded traffic for Centenara Labs is 2.3K monthly website visits, up 820% over the last three months. Centenara Labs's team declined 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EndogenaNewton, United StatesEndogena therapeutics focuses on developing novel treatments for degenerative diseases
$80Mvaluation
Rejuvenate BiomedDiepenbeek, BelgiumScience based healthy aging company developing prescription drugs in healthy aging by repositioning approved drugs
$69Mvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Apeiron
p53 Invest
Daniel Gutenberg
Apeiron Investment Group
Catalio Capital Management
Mubadala Capital
Other known investors1 additional known investor
EIT Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Centenara Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Centenara Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







